Panic Disorders Market Key Players, Market Analysis, Share, Trends And Forecast To 2033

The panic disorders market size has grown strongly in recent years. It will grow from $10.19 billion in 2023 to $10.73 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to antidepressant medications, increased mental health awareness, increased stress levels, access to mental health services, advancements in diagnostic criteria..

The panic disorders market size is expected to see strong growth in the next few years. It will grow to $13.07 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to emerging pharmacological treatments, telepsychiatry services, focus on comorbidities, global mental health initiatives, pharmacogenomics in treatment, public education programs.. Major trends in the forecast period include digital mental health interventions, telemedicine for panic disorder treatment, innovations in medications, neurobiological research, remote monitoring and wearable technology..

Market Overview -
Panic disorder is a specific type of anxiety illness characterized by unanticipated and recurrent attacks of high anxiety accompanied by physical symptoms such as shortness of breath, chest pain, heart palpitations, nausea, and abdominal discomfort. Panic disorder is generally treated with medication and psychotherapy.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13191&type=smp

Rising Number Of Psychiatric Patients Expected To Drive Panic Disorder Market Growth
An increase in the number of psychiatric patients is expected to propel the growth of the panic disorder market going forward. Psychiatric patients are individuals afflicted by psychiatric disorders or mental illnesses, which can disrupt cognition, emotions, and social behavior, resulting in panic disorder or panic attacks marked by sudden intensity. Treatment for psychiatric patients with panic disorder typically involves a combination of therapeutic approaches, medication, and lifestyle changes to alleviate the symptoms of panic attacks, improve the patient's overall quality of life, and help them manage and cope with condition effectively. For instance, in October 2022, according to the State of Mental Health in America 2022 report published by Mental Health America, a US-based non-profit organization associated with mental health promotion, the number of psychiatric patients or adults with any mental illnesses increased to 49,564,000, representing 19.86% of the total US population in 2022, compared with 47,132,000, representing 19.00% of the total US population in 2021. Therefore, the increase in the number of psychiatric patients will drive the growth of the panic disorder market.

Competitive Landscape -
Major companies operating in the panic disorders market report are F. Hoffmann-La Roche Ltd, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH., Baxter Inc, Teva Pharmaceutical Industries Ltd, Mylan N.V., Pfizer Inc., Sun Pharmaceutical Industries Ltd, Bausch Health Companies Inc., H. Lundbeck A/S, Shionogi & Co Ltd., Recordati S.p.A, Neurocrine Biosciences Inc, Neuraxpharm, Actavis Plc., Noven Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd, VistaGen Therapeutics, Valeant Pharmaceuticals International Inc., LIFECARE NEURO PRODUCTS LTD.

Pharmaceutical Companies Focus On Extended-Release Capsules For Panic Disorder Treatment Advancements
Major companies operating in the panic disorder market are focusing on developing advanced medicines, such as extended-release capsules, to sustain their position in the market. Extended-release capsules are medications that release the active ingredient slowly over a while, typically 12 or 24 hours, to treat conditions requiring medication to be taken over a long period. For instance, in May 2023, Granules India Ltd., an India-based pharmaceutical company, received abbreviated new drug application (ANDA) approval from the US Food & Drug Administration (USFDA) for Venlafaxine hydrochloride extended-release capsules. It demonstrates bioequivalence with the reference-listed drug product (RLD), Effexor XR Extended-Release Capsules, manufactured by Upjohn US 2 LLC. Venlafaxine HCl extended-release capsules are prescribed for the management of conditions including generalized anxiety disorder (GAD), major depressive disorder (MDD), panic disorder (PD), and social anxiety disorder (SAD). They work by increasing the levels of serotonin and norepinephrine in the brain, and the dosage is usually started at 75 mg per day and may be increased by the doctor as needed.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/panic-disorders-global-market-report

Key Segments -
The panic disorders market covered in this report is segmented -
1) By Type: Agoraphobia, Social Anxiety Disorder (SAD), Obsessive-Compulsive Disorder (OCD), Bipolar Disorder, Post-Traumatic Stress Disorder (PTSD), Major Depressive Disorder
2) By Treatment: Medication, Beta Blockers, Serotonin And Norepinephrine Reuptake Inhibitors (SNRIs), Benzodiazepines, Anti-Epilepsy, Other Treatments
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administrations
4) By End Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.